and this is our year in a nutshell. Welcome!
IDIBELL ANNUAL REPORT 2017
We are
IDIBELL
Foreword
Gabriel Capellá
Director
While 2016 was a year of change at IDIBELL, 2017 has been a year to take stock of IDIBELL actions, as the 2015-2017 Strategic Plan came to an end. As often happens when completing a plan, we focus on what we are still missing rather on the many achievements. However, it must be noted that the Strategic Plan 2015 -2017 has been completed with a remarkable performance regarding every one of its five main objectives: (i) developing a common research policy with an impact on health; (ii) attracting and retaining talented clinical and translational researchers; (iii) bringing research closer to society; (iv) implementing a culture of transparency; and (v) achieving the viability of the institute through responsible management.
Our stories
(or drag the slider on your right to see some of the year’s scientific highlights)
Scientific production
1110
59
23
AVERAGE IMPACT FACTOR
Open access
491
621
Staff
Women
International staff
Academic staff
Non-academic staff
Scientific culture
1270
472
333
Financial information
Internal resources (trustees)
External resources
Expenses
Cancer
Molecular mechanisms and experimental therapy in oncology
- Colorectal Cancer
- Cell death regulation
- Apoptosis and Cancer
- TGF-beta and cancer
- Hematopoyetic and lymphoid tumors
- Sarcoma
- Radiobiology & Cancer
- Hereditary cancer
- Metabolism and Cancer
- Head and neck diseases
- Neuro-Oncology
- Gynecologic Cancer
- Tumour Angiogenesis
- Cancer Virotherapy and Immunotherapy
- Chemoresistance and predective factors to tumor response and stromal microenvirontment
- Breast cancer
- Resistance and Progression Mechanisms in Prostate Cancer
- Molecular signaling in Cancer
- Clinical Research in Solid Tumors